Ranbaxy in expansion
mode; inducts 4 senior executives
New Delhi, April 19 : RANBAXY Ltd is expanding its presence
in the global and domestic over-the-counter (OTC) and nutraceutical
product segments and has inducted Atul Malhotra from Hindustan Lever
Ltd (HLL) as head (global OTC) and regional director for Middle
Ranbaxy president Brian Tempest told The Financial Express that
atleast four senior level executives have joined the company over
the past two months from various multinationals, including HLL,
Colgate Palmolive, Gillete and Johnson & Johnson (J&J),
to head various positions. These include vice-president (global
HR), director (business finance) and director (marketing).
There has been a lot movement with in the organisation as well,
Dr Tempest said. The head of Australia and New Zealand operations
has been shifted to head German operations, the head of Thailand
operations has been moved to South Africa and there is new head
of Vietnam operations. The country manager of Ranbaxy’s Vietnam
operations has been made managing director of Ranbaxy UK Limited
and Ranbaxy Ireland Limited.
Udai Upendra, earlier with HLL and Colgate Palmolive, has joined
as vice- president (global HR). Lalit Ahluwalia has left Gillette
to join Ranbaxy as director (business finance) while Sanjeev Dani
has been hired from J&J as director (marketing).
“The induction of key people will not only help Ranbaxy revive
its human resource strength, but is intended to push over the counter
and nutraceutical products in overseas and domestic markets,” Dr
The company is aggressively working to increase its range of OTC
and nutraceutuical products in the domestic markets. The company’s
current portfolio of OTC products includes cough and cold and vitamins
and other products like ‘Fenules’ (iron capsules), Revital (ginseng)
and garlic pills in the nutraceutical segment.
In the cough and cold segment, Ranbaxy’s ‘Revital’ is generating
an annual turnover of over Rs 42 crore and ‘Cherrycough’ of over
Rs 10 crore in the domestic market. The company is now working to
push these products aggressively in the international markets as
Ranbaxy’s long-term strategy involves taking the R&D route
for developing new research products in herbal medicine and other
products which will bring the big bucks.
Apart from this, the company is also aggressively looking at entering
the biotechnology sector as well and plans to introduce a healthcare
product in China and foray into ‘branded business’ in the UK. Ranbaxy
is planning to launch new drug formulations for ulcers, hypertension,
psychiatry, cancer and immunosuppressant.